Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer

Basit Öğe Kaydı
dc.contributor.authorCakar, B.
dc.contributor.authorVarol, U.
dc.contributor.authorJunushova, B.
dc.contributor.authorMuslu, U.
dc.contributor.authorOner, P. Gursoy
dc.contributor.authorSurmeli, Z. Gokhan
dc.contributor.authorCirak, Y.
dc.contributor.authorKaraca, B.
dc.contributor.authorSezgin, C.
dc.contributor.authorKarabulut, B.
dc.contributor.authorUslu, R.
dc.date.accessioned2019-10-27T21:52:38Z
dc.date.available2019-10-27T21:52:38Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose: This study aimed at comparing the disease-free survival (DFS) in high-risk TNM stage II colon cancer patients who had been subjected to adjuvant chemotherapy and TNM low-risk stage II patients who did not receive chemotherapy. Methods: : We retrospectively reviewed the medical records of stage II colon cancer patients between January 2006 and December 2011. High-risk patients were defined those with any colonic obstruction/perforation, mucinous histology, inadequate lymph node sampling, T4 disease, lymphatic/vascular or perineural invasion, preoperatively elevated carcinoembryonic antigen (CEA) and high-grade tumor. All patients with high-risk features received adjuvant chemotherapy. Results: There were 42 patients in the high-risk treatment group and 21 patients in the non-treatment (observation) group. There were no significant differences in terms of gender, tumor size, tumor localization, or the number of excised lymph nodes between the groups. The median follow-up time was 33.9 months in the treatment group and 29.3 months in the non-treatment group. Recurrence developed in 4 patients (6.3%), 3 of which were in the treatment group. DFS in both groups was statistically similar. Conclusion: Adjuvant chemotherapy in the high-risk patients resulted in similar DFS as that in the low-risk patients. Although the role of adjuvant chemotherapy for stage II colon cancer is unclear, it is rational to offer adjuvant chemotherapy to patients with high-risk stage II colon cancer.en_US
dc.identifier.endpage376en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue2en_US
dc.identifier.pmid23818348en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage372en_US
dc.identifier.urihttps://hdl.handle.net/11454/47695
dc.identifier.volume18en_US
dc.identifier.wosWOS:000322750700010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbreast canceren_US
dc.subjectERen_US
dc.subjectPRen_US
dc.subjectHER 2en_US
dc.subjectKi-67en_US
dc.subjectneoadjuvant chemotherapyen_US
dc.titleEvaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu